A leading Spanish pharmaceutical company with a global presence is focused on the research, development, and manufacturing of prescription drugs, healthcare products, and animal nutrition. The company seeks to partner with early-stage companies to enrich its current internal drug discovery pipeline and is open to various partnership structures, including co-development, in-licensing, and acquisition. The firm also makes equity investments, and is open to both leading and co-investing. A board or observer seat may be considered on a case-by-case basis. The company is geographically agnostic and open to considering opportunities globally.
The company seeks early-stage assets for its drug discovery pipeline. While small molecules are a primary area of focus, the firm is open to different types of assets, including peptides, antibodies, and platform technologies. However, software and materials are out of scope. The firm is open to all indications and modalities. In terms of development phases, the company is interested in assets ranging from pre-clinical to Phase I.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment